Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Gary A Lyons is Director at Neurocrine Biosciences. OQRO lists 8 transactions filed with the SEC under this name, the latest on Nov 19, 2026, each linked to the official Form 4.
Director
Disclosures on record
8
Companies involved
2
Neurocrine BiosciencesNBIX
6 disclosures · Nov 2026 · 4 sold
Nov 17, 2026Sold~$940Kdisclosed Nov 19
DetailsOfficial recordNov 17, 2026Sold~$680Kdisclosed Nov 19
DetailsNov 17, 2026Sold~$658Kdisclosed Nov 19
DetailsOfficial recordNov 17, 2026Sold~$196Kdisclosed Nov 19
DetailsOfficial recordNov 17, 202615Kdisclosed Nov 19
DetailsOfficial recordNov 17, 202615Kdisclosed Nov 19
DetailsOfficial recordTravere TherapeuticsTVTX
2 disclosures · Oct 2024 · 2 sold
Oct 4, 2024Sold~$304K
DetailsOfficial recordOct 4, 2024Sold~$285K
DetailsOfficial recordGary A Lyons has no open-market purchase on record since 2014 across 2 companies. Sales in 10 of the 13 years since 2014.
Gary A Lyons reported 0 open-market purchases and 32 sales since 2014; no open-market purchase.
| Year | Bought | Sold |
|---|---|---|
| 2026 | — | $2.47M4×4 trades |
| 2024 | — | $4.16M5×5 trades |
| 2023 | — | $3.01M4×4 trades |
| 2022 | — | $3.67M3×3 trades |
| 2021 | — | $1.77M4×4 trades |
| 2019 | — | $1.97M3×3 trades |
| 2018 | — | $4.04M4×4 trades |
| 2017 | — | $729K1×1 trade |
| 2015 | — | $2.07M3×3 trades |
| 2014 | — | $313K1×1 trade |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
As of the latest filing on , Gary A Lyons reported holding 122,141 shares of Neurocrine Biosciences (NBIX), worth about $18.4M at the last close of $151 (Nov 20, 2026). Holdings are also on file at Travere Therapeutics (TVTX); together they are worth about $20.8M. In the last 12 months, Gary A Lyons sold $2.47M in 4 sales.
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Neurocrine Biosciences NBIX | 122,141 | 122K direct | $151 | $18.4M | Nov 17, 2026 |
| Travere Therapeutics TVTX | 51,000 | 51K direct | $47 | $2.4M | Oct 4, 2024 |
Is this Gary A Lyons’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
On the latest SEC Form 4, dated Nov 17, 2026, Gary A Lyons reported holding 122,141 shares of Neurocrine Biosciences (NBIX). At the last close of $151 on Nov 20, 2026, that is about $18.4M. This is the stake disclosed in filings, not a net worth.
No public filing gives Gary A Lyons's net worth. What SEC Form 4 shows is the stock stake: 122,141 shares of Neurocrine Biosciences (NBIX), about $18.4M at the last close, plus holdings in 1 other company, about $20.8M in all. Cash, other investments, property, debts and unexercised options are not in these filings, so the real figure can be much higher or lower.
In SEC filings of the last 12 months, Gary A Lyons reported 4 open-market sales worth $2.47M, and no open-market purchase. Shares withheld for taxes, gifts and option exercises are not counted in these totals.
Gary A Lyons has no open-market purchase on record since 2014 across 2 companies. Sales in 10 of the 13 years since 2014.
In SEC filings since 2014: no open-market purchase is on record; the latest open-market sale is from 2026.
2 companies: Neurocrine Biosciences (NBIX, 2014–2026), Travere Therapeutics (TVTX, 2024).
Gary A Lyons reported 0 open-market purchases and 30 sales here, 2014 to 2026.
Gary A Lyons reported 0 open-market purchases and 2 sales here, 2024.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.